Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Fernlund, Eva; Eriksson, Martin; Söderholm, Jonas; Sunnegårdh, Jan; Naumburg, Estelle

doi:10.1186/s40949-020-00036-w

Journal of Congenital Cardiology

Table 5 Costs, effects and incremental cost-effectiveness ratios (ICER) for different scenarios. Data are expressed as mean value per infant

From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Scenario		Costs	QALYs	Incremental		ICER
Scenario		Costs	QALYs	Costs	QALYs	ICER
Base case	Prophylaxis	12,848 EUR	17.82	−3833 EUR	0.06	Dominance
Base case	No Prophylaxis	16,681 EUR	17.75	−3833 EUR	0.06	Dominance
Time horizon = 1y	Prophylaxis	8834 EUR	0.88	− 1481 EUR	0.01	Dominance
Time horizon = 1y	No Prophylaxis	10,315 EUR	0.88	− 1481 EUR	0.01	Dominance
Time horizon = 5y	Prophylaxis	9341 EUR	3.76	− 1868 EUR	0.01	Dominance
Time horizon = 5y	No Prophylaxis	11,209 EUR	3.74	− 1868 EUR	0.01	Dominance
Time horizon = 10y	Prophylaxis	9964 EUR	6.84	− 2292 EUR	0.02	Dominance
Time horizon = 10y	No Prophylaxis	12,255 EUR	6.81	− 2292 EUR	0.02	Dominance
No asthma	Prophylaxis	11,378 EUR	17.92	− 3563 EUR	0.04	Dominance
No asthma	No Prophylaxis	14,941 EUR	17.88	− 3563 EUR	0.04	Dominance
No RSV-death	Prophylaxis	12,962 EUR	17.85	− 3925 EUR	0.03	Dominance
No RSV-death	No Prophylaxis	16,887 EUR	17.82	− 3925 EUR	0.03	Dominance
No RSV-death, no asthma	Prophylaxis	11,477 EUR	17.95	− 3643 EUR	0.01	Dominance
No RSV-death, no asthma	No Prophylaxis	15,120 EUR	17.94	− 3643 EUR	0.01	Dominance
No delayed heart surgeries	Prophylaxis	10,304 EUR	17.83	−1751 EUR	0.05	Dominance
No delayed heart surgeries	No Prophylaxis	12,055 EUR	17.78	−1751 EUR	0.05	Dominance
Mortality = general population	Prophylaxis	15,337 EUR	27.30	− 5137 EUR	0.10	Dominance
Mortality = general population	No Prophylaxis	20,474 EUR	27.21	− 5137 EUR	0.10	Dominance
No productivity loss	Prophylaxis	10,236 EUR	17.82	− 1667 EUR	0.06	Dominance
No productivity loss	No Prophylaxis	11,903 EUR	17.75	− 1667 EUR	0.06	Dominance
Productivity loss of both parents	Prophylaxis	12,916 EUR	17.82	− 3916 EUR	0.06	Dominance
Productivity loss of both parents	No Prophylaxis	16,832 EUR	17.75	− 3916 EUR	0.06	Dominance

ICER incremental cost-effectiveness ratio, RSV Respiratory syncytial virus, QALY quality-adjusted life year, y years

Back to article page

ISSN: 2056-7251

Contact us

General enquiries: info@biomedcentral.com